Effect of triamterene on potassium excretion in cirrhotic patients receiving furosemide

Thompson, Eugene J.; Torres, Esther; Grosberg, Saul J.; Martínez‐Maldonado, Manuel

doi:10.1002/cpt1977214392

Cited by 8 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is used mainly in patients with hypokalemia caused by other diuretics. [16][17][18][19] Wener et al 20 discovered that combining triamterene (average of 100-200 mg daily) and hydrochlorothiazide (50 mg daily) improved outcomes in 9 patients with congestive HF. Of note, patients in this study did not have diuretic resistance and received varied doses of triamterene.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Triamterene in Hospitalized Patients with Heart Failure and Diuretic Resistance: A Randomized Clinical Trial

Taban-Sadeghi

Khani

Khezripour

et al. 2023

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Due to the potential benefits of triamterene in diuretic resistance, this study was performed to assess whether triamterene add‐on to the standard treatment of heart failure (HF)‐related diuretic resistance improves outcomes. A randomized clinical trial was performed on 45 hospitalized patients with HF with reduced ejection fraction who had diuretic resistance. Patients were randomized to receive either triamterene 50 mg plus hydrochlorothiazide 25 mg (n = 23) or hydrochlorothiazide 50 mg alone (n = 22) until hospital discharge. The primary outcomes were changes in weight and fluid input‐to‐output ratio. Secondary outcomes were respiratory rate, hospitalization duration, serum sodium and potassium, estimated glomerular filtration rate, creatinine, and blood urea nitrogen levels during the study period. The mean (standard deviation) of weight changes was not significantly different in the intervention and the control groups (−6.3 [4.8] vs −4.8 [2.4] kg, respectively; P = .1). No significant differences were shown in input‐to‐output changes between the 2 groups (208.0 [243.4] in the intervention and 600.2 [250.3] in the control group; P = .4). Although the respiratory rate of triamterene‐treated patients decreased, the difference did not reach statistical significance (P = .2). Other secondary outcomes were also similar in both groups. This study did not support the use of triamterene as an add‐on therapy for patients with HF‐related diuretic resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Triamterene can be used as an adjunctive treatment for hypertension and edema caused by congestive HF, liver cirrhosis, and nephrotic syndrome. It is used mainly in patients with hypokalemia caused by other diuretics 16–19 …”

Section: Discussionmentioning

confidence: 99%

Effects of Triamterene in Hospitalized Patients with Heart Failure and Diuretic Resistance: A Randomized Clinical Trial

Taban-Sadeghi

Khani

Khezripour

et al. 2023

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…TA has been utilized either alone [18,19] or in combi nation with potassium-wasting diuretics, such as thia zides [4,[20][21][22] or furosemide [23,24], to both increase natriuresis as well as to minimize the ensuing kaliuresis. TA inhibits passive sodium transport from the luminal side of transporting epithelia [25][26][27], resulting in im paired movement of potassium from cell to lumen, since the latter is functionally coupled to sodium movement.…”

Section: Pharmacodynamicsmentioning

confidence: 99%

Triamterene and the Kidney

Sica¹,

Gehr²

1989

Nephron

View full text Add to dashboard Cite

Triamterene (TA) is a mild ‘potassium-sparing’ diuretic usually employed in combination with other more potent diuretics in the treatment of hypertension. TA pharmacokinetics and pharmacodynamics in normal volunteers, elderly subjects and in patients with renal and hepatic dysfunction are reviewed. A variety of adverse renal effects, such as abnormalities in urinary sediment, nephrolithiasis, interstitial nephritis and acute renal failure, has been reported to occur and is also reviewed. Of particular concern with the increased availability of ‘over-the-counter’ nonsteroidal anti-inflammatory medications (NSAID) is the adverse interaction between TA and NSAID which may culminate in acute renal failure. Although a rare occurrence, the clinician should be aware of potential adverse reactions associated with the use of TA.

show abstract

Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis

Benmassaoud

Freeman

Roccarina

et al. 2020

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundApproximately 20% of people with cirrhosis develop ascites. Several di erent treatments are available; including, among others, paracentesis plus fluid replacement, transjugular intrahepatic portosystemic shunts, aldosterone antagonists, and loop diuretics. However, there is uncertainty surrounding their relative e icacy. ObjectivesTo compare the benefits and harms of di erent treatments for ascites in people with decompensated liver cirrhosis through a network meta-analysis and to generate rankings of the di erent treatments for ascites according to their safety and e icacy. Search methodsWe searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials Registry Platform, and trials registers until May 2019 to identify randomised clinical trials in people with cirrhosis and ascites. Selection criteriaWe included only randomised clinical trials (irrespective of language, blinding, or status) in adults with cirrhosis and ascites. We excluded randomised clinical trials in which participants had previously undergone liver transplantation. Data collection and analysisWe performed a network meta-analysis with OpenBUGS using Bayesian methods and calculated the odds ratio, rate ratio, and hazard ratio (HR) with 95% credible intervals (CrI) based on an available-case analysis, according to National Institute of Health and Care Excellence Decision Support Unit guidance.Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis (Review)

show abstract

Effect of triamterene on potassium excretion in cirrhotic patients receiving furosemide

Cited by 8 publications

References 0 publications

Effects of Triamterene in Hospitalized Patients with Heart Failure and Diuretic Resistance: A Randomized Clinical Trial

Effects of Triamterene in Hospitalized Patients with Heart Failure and Diuretic Resistance: A Randomized Clinical Trial

Triamterene and the Kidney

Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis

Contact Info

Product

Resources

About